Tempest Therapeutics (NASDAQ:TPST) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Tempest Therapeutics (NASDAQ:TPST) issued its quarterly earnings results on Friday. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.11, Zacks reports.

Tempest Therapeutics Stock Performance

Shares of TPST traded down $0.00 during trading hours on Friday, reaching $0.38. The stock had a trading volume of 153,029 shares, compared to its average volume of 881,778. Tempest Therapeutics has a 12 month low of $0.34 and a 12 month high of $9.75. The stock has a market capitalization of $7.64 million, a PE ratio of -0.09 and a beta of -1.54. The company’s 50-day moving average is $0.70 and its two-hundred day moving average is $1.40.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Friday, October 9th. Wall Street Zen upgraded Tempest Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Reduce”.

About Tempest Therapeutics

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s approach is designed to address both tumor cells and the immune environment surrounding them, with the goal of stimulating antitumor immune responses and improving the effectiveness of cancer treatment. Tempest’s pipeline includes TPST-1120, an orally administered, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα). The company has evaluated TPST-1120 in clinical studies involving advanced solid tumors, including hepatocellular carcinoma, and has investigated its use in combination with other cancer therapies.